abstract |
The present invention relates to dibenzoazulene compounds represented by the formula (I) for the inhibition of such mediators in mammals of all diseases and conditions in which tumor necrosis factor alpha (TNF-α) and interleukin 1 (IL-1) are excessively secreted. It relates to pharmaceutical preparations. The compounds of the present invention can also be used to exhibit analgesic action and relieve pain. |